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from NICE regarding inclusion of this methodology within HTA. Conclusions on the 
acceptance of this methodology by NICE cannot be made due to limited examples.
PRM214
Meta-analysis to suPPoRt technology subMissions to health 
technology assessMent authoRities: cRiticisMs by nice and 
evidence Review gRouPs in the uk
Batson S, Webb N, Greenall G
Abacus International, Oxfordshire, UK
Objectives: The quality of evidence used in manufacturers’ submissions to health 
technology assessment (HTA) bodies is an important factor for the success of tech-
nology appraisals (TA). Indirect comparisons (IC) and network meta-analyses (NMA) 
are used in health policy decisions via the clinical effectiveness evidence in HTA 
submissions to the National Institute for Health and Care Excellence (NICE). The 
aim of this study was to: (i) assess the use of ICs and NMAs in HTA submissions 
to NICE; (ii) identify criticisms of ICs and NMAs in TAs generated by NICE and the 
Evidence Review Group (ERG); (iii) provide key insights and recommendations to 
minimise criticism of an IC or NMA in future HTA submissions. MethOds: The 
NICE website was interrogated to identify both TAs and the associated ERG/final 
appraisal document reports published from January 2013 to June 2015 in any thera-
peutic setting. Results: A large proportion of the TAs analysed included ICs or 
NMAs. Common criticisms were related to the identification of data and the study 
selection for inclusion, study heterogeneity and the inadequate reporting of meth-
ods and analyses. cOnclusiOns: The majority of criticisms of evidence synthesis 
submitted to NICE were related to issues around the primary evidence included in 
the analyses rather than the statistical methods of the analyses. To avoid many of 
the criticisms identified in this study a transparent approach to the reporting of the 
ICs and NMAs (and systematic review) is recommended.
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Objectives: Network meta-analysis (NMA) of clinical trial outcomes is usually 
based on Bayesian statistics and hence requires software for Monte Carlo Markov 
chain (MCMC) sampling. The most common choice of software for NMA is WinBUGS, 
in part because there is a large body of WinBUGS code for NMA in the literature; for 
example in the NICE Decision Support Unit (DSU) Technical Support Documents 
(TSD) on evidence synthesis. However, WinBUGS is slow, difficult to use, and bet-
ter, more efficient, options may be available. This project aimed to identify and 
evaluate alternatives to WinBUGS. MethOds: We identified candidate alternatives 
for evaluation via journal articles and websites. We performed an initial examina-
tion against a set of criteria including (a) compatibility with Windows (b) speed (c) 
ease of use (d) publication quality graphics (in the system or ease of linking with 
an external program such as R) (e) ability to handle large datasets within MCMC 
software and (f) cost. We ranked the candidates and then performed a validation 
of the top-ranked choice by running a set of examples found in the NICE DSU TSDs 
to ensure matching of the results. Results: We found nine potential alternatives 
to WinBUGS: OpenBUGS; JAGS; GeMTC; LaplacesDemon; Mamba; PyMC; SAS PROC 
MCMC; MCMCpack; Stan. Stan was the most promising and we tested it against a 
number of datasets used from the NICE guidance. cOnclusiOns: We found Stan, 
an open source program for Bayesian statistical inference, to be the best option for 
NMA. Stan provides an excellent balance of model flexibility, allowing for manual 
user specification, and is easily integrated with R for producing publication qual-
ity graphics. We found it straightforward to learn because it is accompanied by an 
extensive user manual and provides helpful error messages. We recommend that 
NMA practitioners should consider Stan as an alternative to WinBUGS.
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Objectives: Machine learning techniques are used for analysis of large complex 
datasets. Classification is an important part of machine learning applications, it 
defines groups within population. There are many different methods which are 
compare results to determine the best classification. In this study we aim to use 
machine learning techniques to classify OECD countries according to their health 
expenditures. MethOds: Different algorithms can be use in machine learning tech-
niques; C4.5 which is an extension version of ID.3 algorithm and CART algorithm 
are one of these most commonly use algorithms. Random Forest which constructs 
a lot of number of trees is one of another useful technique for solving both clas-
sification and regression problems. In this study we compare classification per-
formances of different decision trees (C4.5, CART) and Random Forest which was 
generated by using 50 trees. We perform this prediction model for predicting OECD 
countries health expenditures for the year 2011. We use number of independent 
variables for this prediction. These are; life expectancy at birth, number of phy-
sicians, number of hospitals, hospital aggregates, alcohol consumption, GDP per 
capita, perceived health status and immunization. We use AUC results and ROC 
curve graph for performance comparison. Results: As a result of this study it was 
seen that classification performances of machine learning techniques were good 
(AUC≥ 0.90) and Random Forest [50] classification performance results much higher 
[AUC= 0.98] than CART (0.95) and C4.5 (0.90). Decision tree graphs shows that GDP 
per capita was a variable which has more information gain for predicting health 
expenditures. cOnclusiOns: To conclude according to our knowledge this is the 
first study applied machine learning classification methods to health expenditure 
data. Future studies will compare classification performances of Random Forest 
using different types of health expenditure datasets, different predictor variables 
while increasing the number of trees in the forest.
size of an RTBCEA that balances its cost and the value of perfect information that 
would remain after its completion.
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Objectives: Quantitative analysis of spontaneous adverse drug reaction reports 
is increasingly used in drug safety research. Signals are detected by disproportion-
ality measures (DM). Different types of DMs are available: a debate is ongoing on 
which performs better. The aim was to evaluate the sensitivity on identification of 
signals with known safety profiles of incretin drugs. MethOds: Adverse Events (AE) 
reported to FDA Adverse Event Reporting System (FAERS) between 2005 and 2014 
were included. To evaluate the impact of warning actions, two separated analysis 
were conducted: restricted to the time before and after a regulatory action. We 
selected 20 AEs for each drug, half as “positive controls” (with a known causal associ-
ation from literature) and half as “negative controls” (with no evidence in literature). 
Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence 
Propagation Neural Network Analysis (BCPNN) and Gamma-Poisson Shrinker (GPS) 
were calculated on 120 combinations of AE-drugs. Correlation between sensitivity 
and number of AEs per year reported for each drug was calculated to evaluate the 
effect of number of reports on sensitivity. Results: The number of reports ana-
lyzed in 2014 was 1,934,607. After warning action, PRR showed a sensitivity of 0.42 
(0.29; 0.55), ROR 0.55 (0.42; 0.68), BCPNN 0.53 (0.40; 0.66) and GPS 0.23 (0.13; 0.36). 
Analog findings were observed before warning actions. The concordance of signals 
identification was good for all pairwise comparison between DMs (> 0.56). The cor-
relation varied among 0.49 (for PRR) and 0.82 (for ROR and BCPNN) after warning 
action. cOnclusiOns: The sensitivity of measures was low (< 0.6), without impact 
of warning actions. ROR and BCPNN showed the most elevated values of sensitivity 
not allowing to determine a clear superiority of neither frequentist nor bayesian 
DMs. As expected, the positive correlation suggests the presence of a strong impact 
on sensitivity of higher number of AEs reported.
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Objectives: Randomized clinical trials of biological products are commonly ana-
lyzed with an intent-to-treat (ITT) approach, whereby patients are analyzed in their 
assigned treatment group regardless of actual treatment received. The ensuing 
switch to second line treatment disturbs randomization, compromising the utility 
of clinical data. The main objective of the study is to discuss how the statistical 
procedure of inverse probability of censoring weighted (IPCW) analysis may be used 
in this situation MethOds: The first step in the IPCW analysis is to predict the 
probability of switch on the basis of each patient’s baseline characteristics, such 
as age, sex, race, the time from diagnosis to randomization, and biological markers 
by fitting a logistic regression model. Finally, Overall Survival (OS) is analyzed with 
the censored data set and observations weighted by the inverse of the predicted 
probability of censoring. The method was illustrated for one clinical trial evaluating 
the effect of one monoclonal antibody combined with gemcitabine in patients with 
advanced pancreatic cancer. Results: A total of 192 patients were randomized 
(average age 63.6 ±10 years; 60% male; 69% ECOG PS 0), Of 96 patients enrolled in the 
nimotuzumab arm (OSAG), 40 patients (41.7%) switch to second line, while in the 
Placebo arm 41(42.7%) switch to the second line. The hazard ratio and 95% CI for OS 
was 0.83 (95% CI, 0.62 to 1.12) for ITT, was 0.75 (95% CI, 0.51 to 1.12) for the censored 
analysis, and for IPCW was 0.82 (95% CI, 0.67 to 0.98). cOnclusiOns: The switch 
to second line treatment affects efficacy results of the ITT analysis of the nimotu-
zumab plus Gemcitabine therapy in pancreatic cancer. Additional IPCW analysis 
indicates that the benefit of the molecular antibody, nimotuzumab, is greater than 
that reflected by the ITT estimate.
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Objectives: Meta-analysis of survival data is most commonly performed by using 
the individual summary statistic hazard ratio (HR) from each study as an appropri-
ate measure of effect. The aim of this study was to (i) assess the literature reporting 
on the use of meta-analysis of parametric survival curves, an alternative novel 
method for the evidence synthesis of survival data; (ii) assess technology apprais-
als (TAs) submitted to the National Institute for Health and Care Excellence (NICE) 
to determine whether this novel method has been accepted within UK Health 
Technology Assessment (HTA). MethOds: Embase, Medline and the Cochrane 
Library were searched to identify publications reporting on novel statistical meth-
ods. The NICE website was interrogated to identify oncology TAs, the associated 
Evidence Review Group (ERG) and final appraisal document (FAD) as published 
between 2011 and 2014 which reported novel statistical methods. Results: Four 
publications reported on the use of meta-analysis of parametric survival curves. 
Of the most recent 60 NICE TAs, a single TA included the use of meta-analysis of 
parametric survival curves. cOnclusiOns: Meta-analysis of survival curves has 
been developed to address limitations which arise where the proportional hazards 
assumption does not hold for survival curves; however, to date the method has 
not been validated by independent statisticians and currently there is no guidance 
